Ignite Creation Date:
2025-12-25 @ 3:00 AM
Ignite Modification Date:
2026-02-27 @ 4:32 PM
Study NCT ID:
NCT03013933
Status:
COMPLETED
Last Update Posted:
2024-02-22
First Post:
2017-01-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Sponsor:
City of Hope Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-05-03
Start Date Type:
ACTUAL
Primary Completion Date:
2022-05-24
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-05-24
Completion Date Type:
ACTUAL
First Submit Date:
2017-01-04
First Submit QC Date:
None
Study First Post Date:
2017-01-09
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-02-20
Last Update Post Date:
2024-02-22
Last Update Post Date Type:
ACTUAL